p53 — LLMpedia

Contents

p53 The protein encoded by TP53 is a nuclear phosphoprotein that acts as a transcriptional regulator and tumor suppressor, coordinating responses to DNA damage, oncogene activation, hypoxia, and metabolic stress. Discovered through studies involving Columbia University, Cold Spring Harbor Laboratory, National Cancer Institute, Howard Hughes Medical Institute, and researchers such as Arnold J. Levine, David Lane, Bert Vogelstein, and Moshe Oren, the protein is central to pathways implicated in diverse cancers including breast cancer, lung cancer, colorectal cancer, leukemia, and glioblastoma. Its dysfunction by mutation, deletion, or viral interaction (e.g., Human papillomavirus E6) underlies therapeutic strategies developed at institutions like Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and pharmaceutical companies such as Roche and Merck & Co..

Introduction

p53 is encoded by the TP53 gene located on chromosome 17 (human). Classic studies from groups at Cambridge University, Institut Pasteur, and Harvard Medical School established its role as a "guardian of the genome" in response to genotoxic stress, a concept widely cited in work from National Institutes of Health, European Molecular Biology Laboratory, and Nobel-recognized discoveries associated with researchers like James Watson and Francis Crick-era genetics. Clinical correlations between TP53 status and prognosis were revealed in cohorts from Johns Hopkins University, Mayo Clinic, and multinational consortia including The Cancer Genome Atlas.

The protein contains an N-terminal transactivation domain, a central DNA-binding core, and a C-terminal oligomerization domain; these domains were characterized using structural biology platforms at European Synchrotron Radiation Facility, Brookhaven National Laboratory, and investigators from Stanford University and University of California, Berkeley. High-resolution structures solved by groups affiliated with Max Planck Institute and Cold Spring Harbor Laboratory used X-ray crystallography and NMR to define the DNA-binding surface and zinc coordination sites, informing biochemical studies by laboratories at University of Cambridge and Yale University. The tetrameric assembly essential for sequence-specific binding was studied alongside interactions with cofactors characterized in work from Princeton University and Imperial College London.

p53 regulates cell-cycle checkpoints through transcriptional activation of targets including CDKN1A (p21) and influences apoptosis via BAX and PUMA, findings supported by research from University of Chicago, Cornell University, and University of Pennsylvania. It integrates signals from kinases such as ATM, ATR, CHK1, and CHK2 elucidated in consortia involving European Research Council-funded groups and centers like Institut Curie. In stress responses connected to hypoxia and metabolic reprogramming, p53 cooperates with regulators studied at Massachusetts Institute of Technology and University of Oxford, linking to autophagy pathways explored by teams at Weizmann Institute of Science and Karolinska Institutet.

Loss-of-function mutations in TP53 are among the most frequent alterations in human malignancies, documented across datasets from SEER program, International Agency for Research on Cancer, and The Cancer Genome Atlas. Classic tumor models developed at Cold Spring Harbor Laboratory and Sloan Kettering demonstrated that p53 inactivation cooperates with oncogenes such as RAS and MYC, paralleling findings in animal models from The Jackson Laboratory and European Molecular Biology Laboratory. Viral oncogenesis studies showed that Human papillomavirus and SV40 large T antigen can abrogate p53 function, a mechanism explored in collaborations involving Rockefeller University and UCSF.

p53 activity is tightly controlled by ubiquitination via MDM2 and MDM4, pathways dissected in seminal work at Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory. Phosphorylation by ATM/ATR, acetylation by p300/CBP, methylation by SET7/9, and SUMOylation were characterized in studies from Max Planck Institute for Molecular Genetics and Kyoto University. Crosstalk with E3 ligases, deubiquitinases, and chaperones was elucidated through collaborative networks including European Molecular Biology Laboratory, Broad Institute, and pharmaceutical research groups at Pfizer.

TP53 status informs prognosis and treatment response in trials conducted by cooperative groups like European Organisation for Research and Treatment of Cancer and SWOG. Therapeutic strategies include restoration of wild-type function using small molecules (developed by companies such as AstraZeneca and Novartis), inhibition of MDM2–p53 interaction exemplified by agents from Amgen and Hoffmann-La Roche, gene therapy approaches trialed at Mayo Clinic and University College London, and immunotherapeutic modalities investigated in partnerships with National Cancer Institute and biotech firms like Moderna. Biomarker-driven trials cataloged by ClinicalTrials.gov and precision oncology initiatives from Flatiron Health leverage TP53 sequencing platforms developed by Illumina and Thermo Fisher Scientific.

Category:Proteins Category:Tumor suppressors